Actions

CD13: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
Line 16: Line 16:
<span style="color:navy">'''Diagnostic role'''</span>  
<span style="color:navy">'''Diagnostic role'''</span>  


:Together with other markers (CD117, CD33 and MPO), CD13 can be used to identify myeloid lineage in acute myeloid leukaemia. CD13 is also expressed by myelomonocytic and monocytic leukaemia cells.
*Together with other markers (CD117, CD33 and MPO), CD13 can be used to identify myeloid lineage in acute myeloid leukaemia. CD13 is also expressed by myelomonocytic and monocytic leukaemia cells.


:Expression is not always found - it is often absent on more primitive AML cases as well as on those with erythroid or megakaryoblastic differentiation
*Expression of CD34 is not required to diagnose AML - CD13 is often absent on more primitive AML cases as well as on those with erythroid or megakaryoblastic differentiation; while aberrant expression in ALL is recognised to occur in around 30% of patients and it is regarded as less specific than CD117 or MPO.
 
:Aberrant expression in ALL occurs in around 30% of patients  
 
:Overall high sensitivity, but may be less specific than CD117 or MPO.
   
   



Revision as of 09:07, 27 April 2023



Normal expression and function

CD13 is a cell surface enzyme whose function varies between tissues; its precise function in myeloid cells is unclear. The pattern of expression is similar to other pan-myeloid markers (CD117 and CD33), but with levels generally increasing during maturation (contrasting with CD117 and CD33 whose expression decreases). Maturation of normal myeloid cells may therefore be partly idicated through the relative CD33/13 expression.


Diagnostic role

  • Together with other markers (CD117, CD33 and MPO), CD13 can be used to identify myeloid lineage in acute myeloid leukaemia. CD13 is also expressed by myelomonocytic and monocytic leukaemia cells.
  • Expression of CD34 is not required to diagnose AML - CD13 is often absent on more primitive AML cases as well as on those with erythroid or megakaryoblastic differentiation; while aberrant expression in ALL is recognised to occur in around 30% of patients and it is regarded as less specific than CD117 or MPO.


Other relevant information:


Expression is not restricted to myeloid cells, and CD13 is particularly expressed on small intestinal and renal tubular epithelial cells and synaptic membranes from the CNS.



SUMMARY TABLES

Expression of CD13 by cells with early differentiation: ALL and haematogones
pro-B ALL early pre-B ALL pre-B ALL B-ALL pro T-ALL mat T-ALL AML Hgns
poss poss poss rare rare rare strg freq

* low expression correlates with subtype e.g. APML

Expression of CD38 by mature B cells: B-lymphoproliferative disorders
CLL MCL FL HCL HCv MZL LPL PCL
rare rare rare rare rare rare rare rare

*May indicate adverse prognostic when present on more than 20% of cells

**May be weak


1. Colour key: - the likelihood of any individual case expressing this marker, indicated by colour:

Rare (<5%) Possible (5-20%) Likely (20-40%) Frequent (40-80%) Expected (80-100%)

2. Text key: - where expression level is characteristic of a disorder this is indicated by text:

abs = absent expression, wk = weak expression, mod = moderate expression, stg = strong expression, sub = expression may be on a sub-population of cells

SUMMARY TABLES


Expression by acute leukaemias and by haematogones

Notes

In ALL the expression of CD13 is more likely in B-ALL but is also seen in T-ALL

In AML CD13 is expressed in around 80% of cases

In haematogones expression of CD13 is very frequent


Expression by B-lymphoproliferative disorders


CD13 expression: primitive cell types
B ALL T ALL AML ETP ALL MPAL Hgns
rare freq strg strg freq strg
CD13 expression: B cell neoplasms
CLL MCL FL HCL MZL LPL PCL
rare rare rare rare rare rare rare



KEY


1. Colour key: - the likelihood of any individual case expressing this marker, indicated by colour:

Limited studies Rare (<5%) Possible (5-20%) Likely (20-40%) Frequent (40-80%) Expected (80-100%)